

## DISCLAIMER


Electronic versions of the exhibits in these minutes may not be complete.

This information is supplied as an informational service only and should not be relied upon as an official record.

Original exhibits are on file at the Legislative Counsel Bureau Research Library in Carson City.

Contact the Library at (775) 684-6827 or [library@lcb.state.nv.us](mailto:library@lcb.state.nv.us).

A Patient's Guide to



ORIGINALS ARE ON FILE IN  
THE RESEARCH LIBRARY

ASSEMBLY COMMERCE & LABOR 103  
DATE: 4/09/03 ROOM: 4100 EXHIBIT FF  
SUBMITTED BY: Bucky Martin

|   |    |
|---|----|
| INTRODUCTION .....                                | 4  |
| Clinical Trials .....                             | 4  |
| What Are the Benefits for Me? .....               | 5  |
| It Sounds Interesting but Complicated. ....       | 5  |
| CLINICAL TRIAL INFORMATION .....                  | 6  |
| Protocol .....                                    | 6  |
| Participant Selection .....                       | 7  |
| Eligibility .....                                 | 7  |
| Exclusion Criteria .....                          | 8  |
| Informed Consent .....                            | 8  |
| Selection and Randomization .....                 | 9  |
| Types of Clinical Trials .....                    | 10 |
| Single-Blind, Double-Blind, and Open Trials ..... | 10 |
| Phases I Through IV Trials .....                  | 11 |
| Adjuvant Therapy Trials .....                     | 13 |
| Treatment Information and Instructions .....      | 13 |
| Treatment Regimen .....                           | 13 |
| Dose and Body Surface Area .....                  | 14 |
| Adverse Reactions (Side Effects) .....            | 14 |
| Crossover .....                                   | 15 |
| Follow-up .....                                   | 15 |
| EVALUATION OF TRIAL RESULTS .....                 | 16 |
| Clinical End Points: Effectiveness .....          | 16 |
| Duration of Response .....                        | 17 |
| Time to Tumor Progression .....                   | 17 |
| Survival .....                                    | 18 |
| Clinical End Points: Quality of Life .....        | 18 |
| Performance Level, Performance Status .....       | 19 |
| Clinical End Points: Toxicity .....               | 19 |
| IN CONCLUSION .....                               | 21 |
| QUESTIONS YOU MAY WANT TO ASK .....               | 21 |



## **INTRODUCTION**

This resource has been developed to assist you in making the decision whether or not to participate in a clinical trial. This booklet describes a clinical trial, how it works, and who is included, and it gives you an overview of the process. The Table of Contents in the front of this booklet will help you find the information you need.

### **Clinical Trials**

A clinical trial looks at new cancer treatments or new schedules. The treatments may be looked at to see how effective they are on their own or in comparison to existing treatments.

A clinical trial has nothing to do with lawyers or courtrooms, although there will be a verdict. A clinical trial looks at new treatments or a new way of using existing treatments in an effort to find a better way to treat cancer. The result of a trial is the verdict. The new treatment is evaluated to see if it is better than or no different from standard or existing therapy.

Many people worry that they might receive no drug (a placebo) if they enter a trial. In a cancer clinical trial, all participants receive either standard treatment or a new treatment. Standard treatment is the most common therapy used today. The treatment may be a new drug, a combination of a new drug with existing treatments, or a different way of giving the standard treatment.

If the treatment in a clinical trial does not work for you, you can still receive other treatments. Trial participation does NOT exclude a person from additional or different treatment.

